ANI Pharmaceuticals (ANIP) Rating Lowered to Hold at ValuEngine

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Wednesday, ValuEngine reports.

Several other analysts also recently issued reports on the company. BidaskClub downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of ANI Pharmaceuticals in a report on Monday. Raymond James downgraded ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and increased their price target for the company from $73.00 to $82.00 in a report on Friday, May 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $89.00 price target on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. Finally, Zacks Investment Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 30th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $84.25.

Shares of ANIP stock traded down $0.63 on Wednesday, reaching $69.14. 104,701 shares of the stock were exchanged, compared to its average volume of 87,476. The company has a market cap of $836.09 million, a price-to-earnings ratio of 15.00 and a beta of 2.37. The company has a quick ratio of 0.67, a current ratio of 0.92 and a debt-to-equity ratio of 0.33. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $74.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The firm had revenue of $52.90 million during the quarter, compared to the consensus estimate of $50.57 million. During the same period in the prior year, the firm earned $1.32 EPS. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. As a group, analysts expect that ANI Pharmaceuticals will post 5.97 earnings per share for the current fiscal year.

In related news, SVP Robert W. Schrepfer sold 4,651 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total value of $299,663.93. Following the completion of the sale, the senior vice president now directly owns 53,484 shares in the company, valued at approximately $3,445,974.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Arthur Przybyl sold 27,625 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,280 shares of company stock valued at $5,010,337. 24.70% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $54,000. Quantamental Technologies LLC grew its stake in shares of ANI Pharmaceuticals by 169.4% during the first quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 542 shares in the last quarter. South Dakota Investment Council acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at about $45,000. BNP Paribas Arbitrage SA grew its stake in shares of ANI Pharmaceuticals by 55,466.7% during the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 1,664 shares in the last quarter. Finally, Truvestments Capital LLC acquired a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $140,000. Institutional investors own 60.02% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Story: Understanding Average Daily Trade Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.